Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial.
Jung Yong HongHee Jin ChoJason K SaXiaoqiao LiuSang Yun HaTaehyang LeeHajung KimWonseok KangDong Hyun SinnGeum-Youn GwakMoon Seok ChoiJoon Hyeok LeeKwang Cheol KohSeung Woon PaikHee Chul ParkTae Wook KangHyunchul RhimSu Jin LeeRazvan CristescuJeeyun LeeYong Han PaikHo Yeong LimPublished in: Genome medicine (2022)
NCT#03163992 (first posted: May 23, 2017).